\-\ Texto\\:\\ \ \(0\)\
\-\ non\\-localizing\\ neurologic\\ exam\ \(0\)\
\-\ \\â\\€\\¢\\ large\\ central\\,\\ heterogeneous\\ mass\\ involving\\ the\\ bifrontal\\ lobes\\ with\\surrounding\\ edema\\.\\ \\Â\\ \ \(0\)\
\-\ \\â\\€\\¢\\ the\\ lesion\\ itself\\ demonstrates\\ multiple\\ apparent\\ cystic\\regions\\ some\\ with\\ fluid\\ levels\\ with\\ diffuse\\ heterogeneous\\ enhancement\\.\\ \\Â\\ \ \(0\)\
\-\ \\â\\€\\¢\\ portions\\ of\\ the\\ anterior\\ cerebral\\ artery\\ course\\ through\\ portions\\ of\\ this\\lesion\\.\\ \ \(0\)\
\-\ \\â\\€\\¢\\ glioblastoma\\ is\\ the\\ diagnosis\\ of\\ exclusion\\,\\ although\\ an\\ aggressive\\\\ oligodendroglioma\\ or\\ hemorrhagic\\ metastasis\\ are\\ not\\ entirely\\ excluded\ \(0\)\
\-\ glioblastoma\\ multiforme\\ \\(diffuse\\ astrocytoma\\ grade\\ 4\\)\ \(0\)\
\-\ \\â\\€\\¢\\ diffuse\\ astrocytoma\\ high\\ grade\\ \\(gr\\ 4\\ \\-\\ glioblastoma\\)\ \(0\)\
\-\ \\â\\€\\¢\\ oligodendroglioma\ \(1\)\
\-\ \\â\\€\\¢\\ oligoastrocytoma\ \(0\)\
\-\ \\â\\€\\¢\\ primary\\ cns\\ lymphoma\ \(0\)\
\-\ 51\\ y\\.o\\.\\ man\\ with\\ severe\\ headache\\ for\\ four\\ days\ \(1\)\
\-\ \\â\\€\\¢\\ clinical\\ manifestations\\ \\(in\\ who\\ grade\\ iii\\-iv\\ lesions\\)\\(1\\)\ \(0\)\
\-\ \\Â\\»\\ headache\\ 53\\-57\\%\ \(0\)\
\-\ \\Â\\»\\ seizure\\ 56\\%\\ vs\\ \\ 23\\%\ \(0\)\
\-\ \\Â\\»\\ misc\\ neuro\\ deficits\\ \\(amnesia\\,\\ motor\\ weakness\\)\\ \\>20\\%\ \(0\)\
\-\ \\â\\€\\¢\\ primary\\ management\\ is\\ resection\ \(0\)\
\-\ \\Â\\»\\ survival\\ is\\ poor\\ \\-\\ \\ mean\\ 12\\-15\\ mos\\ \\(2\\)\ \(0\)\
\-\ \\Â\\»\\ 5yr\\ survival\\ around\\ 15\\%\\ \\(2\\)\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ glioblastoma\\:\\ 0\\.30563908456584654\ \(0\)\
\-\ grade\\:\\ 0\\.22039275892254076\ \(0\)\
\-\ oligodendroglioma\\:\\ 0\\.2144512069452586\ \(0\)\
\-\ survival\\:\\ 0\\.19941232578516804\ \(0\)\
\-\ portions\\:\\ 0\\.19418435521874466\ \(0\)\
\-\ diffuse\\:\\ 0\\.19220697195800157\ \(0\)\
\-\ misc\\:\\ 0\\.1561195028024316\ \(0\)\
\-\ amnesia\\:\\ 0\\.1561195028024316\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.15424798680038945\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.1478869397044478\ \(0\)\
\-\ oligoastrocytoma\\:\\ 0\\.14697078839790534\ \(0\)\
\-\ 5yr\\:\\ 0\\.14697078839790534\ \(0\)\
\-\ headache\\:\\ 0\\.1408539216343696\ \(0\)\
\-\ 15\\:\\ 0\\.13807137079521906\ \(0\)\
\-\ bifrontal\\:\\ 0\\.1298579011148336\ \(0\)\
\-\ mos\\:\\ 0\\.12729501333355223\ \(0\)\
\-\ primary\\:\\ 0\\.12563873032770334\ \(0\)\
\-\ gr\\:\\ 0\\.12505338371361044\ \(0\)\
\-\ exclusion\\:\\ 0\\.11963963538530901\ \(0\)\
\-\ mean\\:\\ 0\\.11263935180093072\ \(0\)\
\-\ entirely\\:\\ 0\\.11112495753825012\ \(0\)\
\-\ multiforme\\:\\ 0\\.1064633751517127\ \(0\)\
\-\ manifestations\\:\\ 0\\.10468869055054618\ \(0\)\
\-\ itself\\:\\ 0\\.10370258853610392\ \(0\)\
\-\ excluded\\:\\ 0\\.1004906530712804\ \(0\)\
\-\ lesion\\:\\ 0\\.09795865040581864\ \(0\)\
\-\ 51\\:\\ 0\\.09753994248837808\ \(0\)\
\-\ cns\\:\\ 0\\.09540531639676086\ \(0\)\
\-\ 56\\:\\ 0\\.09540531639676086\ \(0\)\
\-\ neuro\\:\\ 0\\.09520520635651944\ \(0\)\
\-\ hemorrhagic\\:\\ 0\\.08861937973327455\ \(0\)\
\-\ aggressive\\:\\ 0\\.08834594446357548\ \(0\)\
\-\ deficits\\:\\ 0\\.08781128797557128\ \(0\)\
\-\ regions\\:\\ 0\\.08768008107168819\ \(0\)\
\-\ poor\\:\\ 0\\.08617628947075456\ \(0\)\
\-\ apparent\\:\\ 0\\.08546923729908254\ \(0\)\
\-\ lobes\\:\\ 0\\.08523962309914837\ \(0\)\
\-\ seizure\\:\\ 0\\.0850129154861931\ \(0\)\
\-\ 23\\:\\ 0\\.08424130300877265\ \(0\)\
\-\ is\\:\\ 0\\.08393428399423773\ \(0\)\
\-\ four\\:\\ 0\\.08279117444383971\ \(0\)\
\-\ neurologic\\:\\ 0\\.08163531132635327\ \(0\)\
\-\ around\\:\\ 0\\.081542273910489\ \(0\)\
\-\ the\\:\\ 0\\.08154106503533241\ \(0\)\
\-\ motor\\:\\ 0\\.08126602685614207\ \(0\)\
\-\ levels\\:\\ 0\\.08099397612220015\ \(0\)\
\-\ with\\:\\ 0\\.08001935074291708\ \(0\)\
\-\ vs\\:\\ 0\\.07793989549574379\ \(0\)\
\-\ course\\:\\ 0\\.0754632217443839\ \(0\)\
\-\ management\\:\\ 0\\.0754632217443839\ \(0\)\
\-\ metastasis\\:\\ 0\\.07487809906722459\ \(0\)\
\-\ weakness\\:\\ 0\\.07456110561891337\ \(0\)\
\-\ involving\\:\\ 0\\.07155955815503397\ \(0\)\
\-\ cerebral\\:\\ 0\\.0707796237898894\ \(0\)\
\-\ although\\:\\ 0\\.06955077001012835\ \(0\)\
\-\ central\\:\\ 0\\.06822352125675811\ \(0\)\
\-\ surrounding\\:\\ 0\\.0681355129112182\ \(0\)\
\-\ 20\\:\\ 0\\.06590938278361362\ \(0\)\
\-\ resection\\:\\ 0\\.06548795952176698\ \(0\)\
\-\ clinical\\:\\ 0\\.06474625260890518\ \(0\)\
\-\ severe\\:\\ 0\\.06467374375570249\ \(0\)\
\-\ days\\:\\ 0\\.06467374375570249\ \(0\)\
\-\ some\\:\\ 0\\.06428010895913264\ \(0\)\
\-\ artery\\:\\ 0\\.06345016916898713\ \(0\)\
\-\ cystic\\:\\ 0\\.06152943793954418\ \(0\)\
\-\ edema\\:\\ 0\\.06093239391099879\ \(0\)\
\-\ lymphoma\\:\\ 0\\.06084452948810625\ \(0\)\
\-\ through\\:\\ 0\\.060815336878092936\ \(0\)\
\-\ of\\:\\ 0\\.05997867581268186\ \(0\)\
\-\ fluid\\:\\ 0\\.05898679850669194\ \(0\)\
\-\ enhancement\\:\\ 0\\.058803376806996384\ \(0\)\
\-\ lesions\\:\\ 0\\.058673501964633466\ \(0\)\
\-\ high\\:\\ 0\\.05806288615385077\ \(0\)\
\-\ who\\:\\ 0\\.05778982988050724\ \(0\)\
\-\ anterior\\:\\ 0\\.05704197775851004\ \(0\)\
\-\ man\\:\\ 0\\.054086482493721756\ \(0\)\
\-\ diagnosis\\:\\ 0\\.0529606943829297\ \(0\)\
\-\ exam\\:\\ 0\\.05142902113938362\ \(0\)\
\-\ demonstrates\\:\\ 0\\.05132569587811298\ \(0\)\
\-\ large\\:\\ 0\\.05118884965527708\ \(0\)\
\-\ multiple\\:\\ 0\\.04997025933144048\ \(0\)\
\-\ not\\:\\ 0\\.0403316130410734\ \(0\)\
\-\ an\\:\\ 0\\.039066876261387384\ \(0\)\
\-\ mass\\:\\ 0\\.039023626633323136\ \(0\)\
\-\ are\\:\\ 0\\.038766299472625665\ \(0\)\
\-\ or\\:\\ 0\\.03554076859966863\ \(0\)\
\-\ this\\:\\ 0\\.035105125676671775\ \(0\)\
\-\ for\\:\\ 0\\.030964890977820403\ \(0\)\
\-\ in\\:\\ 0\\.0254148960354761\ \(0\)\
